Vanta Bioscience
BSE: VANTABIO · Healthcare Research, Analytics & Technology
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vanta Bioscience's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vanta Bioscience is a preclinical contract research organisation providing toxicology, safety assessment, and efficacy testing services. It supports the pharmaceutical, medical device, cosmetics, and chemical industries by ensuring compliance with international regulatory standards.
Business Model
The company generates revenue by offering specialised scientific research services and laboratory testing on a contract basis. It leverages its high-end research infrastructure to assist clients in the early stages of the drug discovery and chemical safety value chain.
Growth Outlook
Growth is driven by the increasing demand for outsourced preclinical research and the company's focus on maintaining international Good Laboratory Practice standards. The firm aims to capture further market share by providing niche research services to both domestic and global clients.
Key Risks
- Regulatory Compliance Risk. Failure to maintain international Good Laboratory Practice standards could result in the loss of accreditation and client contracts.
- Client Concentration Risk. As a small-cap entity, the company may be vulnerable to the loss of key pharmaceutical or chemical industry clients.
- Operational Risks. The business relies heavily on specialised research infrastructure, making it susceptible to technical failures or facility-related disruptions.
- Market Competition. The preclinical research sector is highly competitive, with pressure from larger global contract research organisations.
Start your research today
Unlock AI insights, financials, peers and live data on Vanta Bioscience and 5,000+ companies — free.
Peers · Healthcare Research, Analytics & Technology
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Vanta BioscienceVANTABIO | ₹14 Cr | — | — | — | 56.0% | — | — | — |
Indegene Ltd.INDGN | ₹13,950 Cr | 34.65 | 19.04 | 30.4% | 18.8% | 13.9% | 17.4% | +6.8% |
Suven Life Sciences LimitedSUVEN | ₹9,624 Cr | -24.51 | -27.84 | 17.3% | -557.4% | -100.5% | -99.8% | +70.6% |
Vimta LabsVIMTALABS | ₹2,759 Cr | 34.59 | 17.54 | 15.2% | 37.3% | 19.1% | 24.1% | -7.3% |
Fabtech Technologies LimitedFABTECH | ₹656 Cr | 10.68 | 8.96 | — | 16.3% | 11.6% | 14.1% | — |
Take SolutionsTAKE | ₹239 Cr | 18.77 | 38.28 | — | 7.4% | 49.8% | 24.2% | +60.9% |
As of Mar 2026
Financials
Vanta Bioscience
BSE: VANTABIO · Healthcare Research, Analytics & Technology
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vanta Bioscience's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vanta Bioscience is a preclinical contract research organisation providing toxicology, safety assessment, and efficacy testing services. It supports the pharmaceutical, medical device, cosmetics, and chemical industries by ensuring compliance with international regulatory standards.
Business Model
The company generates revenue by offering specialised scientific research services and laboratory testing on a contract basis. It leverages its high-end research infrastructure to assist clients in the early stages of the drug discovery and chemical safety value chain.
Growth Outlook
Growth is driven by the increasing demand for outsourced preclinical research and the company's focus on maintaining international Good Laboratory Practice standards. The firm aims to capture further market share by providing niche research services to both domestic and global clients.
Key Risks
- Regulatory Compliance Risk. Failure to maintain international Good Laboratory Practice standards could result in the loss of accreditation and client contracts.
- Client Concentration Risk. As a small-cap entity, the company may be vulnerable to the loss of key pharmaceutical or chemical industry clients.
- Operational Risks. The business relies heavily on specialised research infrastructure, making it susceptible to technical failures or facility-related disruptions.
- Market Competition. The preclinical research sector is highly competitive, with pressure from larger global contract research organisations.
Start your research today
Unlock AI insights, financials, peers and live data on Vanta Bioscience and 5,000+ companies — free.
Peers · Healthcare Research, Analytics & Technology
As of Mar 2026